US20080057116A1 - Emu Oil and Fruit Composition - Google Patents
Emu Oil and Fruit Composition Download PDFInfo
- Publication number
- US20080057116A1 US20080057116A1 US11/572,851 US57285105A US2008057116A1 US 20080057116 A1 US20080057116 A1 US 20080057116A1 US 57285105 A US57285105 A US 57285105A US 2008057116 A1 US2008057116 A1 US 2008057116A1
- Authority
- US
- United States
- Prior art keywords
- composition
- cherries
- emu oil
- fruit
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 239000010776 emu oil Substances 0.000 title claims abstract description 29
- 235000013399 edible fruits Nutrition 0.000 title claims abstract description 21
- 235000019693 cherries Nutrition 0.000 claims description 39
- 239000000843 powder Substances 0.000 claims description 8
- 239000003921 oil Substances 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 6
- 235000010208 anthocyanin Nutrition 0.000 claims description 5
- 229930002877 anthocyanin Natural products 0.000 claims description 5
- 239000004410 anthocyanin Substances 0.000 claims description 5
- 150000004636 anthocyanins Chemical class 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 5
- 240000005662 Aronia melanocarpa Species 0.000 claims description 4
- 235000007425 Aronia melanocarpa Nutrition 0.000 claims description 4
- 244000294611 Punica granatum Species 0.000 claims description 4
- 235000014360 Punica granatum Nutrition 0.000 claims description 4
- 244000058477 Sambucus melanocarpa Species 0.000 claims description 4
- 235000007052 Sambucus melanocarpa Nutrition 0.000 claims description 4
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 4
- 240000000851 Vaccinium corymbosum Species 0.000 claims description 4
- 240000001717 Vaccinium macrocarpon Species 0.000 claims description 4
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 4
- 235000011022 black elderberry Nutrition 0.000 claims description 4
- 235000021014 blueberries Nutrition 0.000 claims description 4
- 235000021019 cranberries Nutrition 0.000 claims description 4
- 239000007903 gelatin capsule Substances 0.000 claims description 4
- 235000021018 plums Nutrition 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 229930003935 flavonoid Natural products 0.000 claims description 3
- 150000002215 flavonoids Chemical class 0.000 claims description 3
- 235000017173 flavonoids Nutrition 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- -1 conditioners Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 235000013824 polyphenols Nutrition 0.000 claims description 2
- 239000002453 shampoo Substances 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 241000167854 Bourreria succulenta Species 0.000 claims 4
- 240000006028 Sambucus nigra Species 0.000 claims 1
- 235000003142 Sambucus nigra Nutrition 0.000 claims 1
- 235000008995 european elder Nutrition 0.000 claims 1
- 230000000699 topical effect Effects 0.000 abstract description 3
- 230000037406 food intake Effects 0.000 abstract 1
- 241001290151 Prunus avium subsp. avium Species 0.000 description 37
- 240000002878 Prunus cerasus Species 0.000 description 7
- 235000005805 Prunus cerasus Nutrition 0.000 description 7
- 239000012141 concentrate Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 235000014441 Prunus serotina Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 230000007407 health benefit Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 244000007021 Prunus avium Species 0.000 description 1
- 235000010401 Prunus avium Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229940093797 bioflavonoids Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 235000021579 juice concentrates Nutrition 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/925—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- the invention relates to compositions suitable for topical application to human skin and suitable for ingesting, and, more particularly, to natural compositions comprising emu oil and various fruits.
- Emu oil also known as kalaya oil
- Emu oil is rendered from the bird's fat. It is used in cosmetics and cosmetic related items, including wrinkle retarding emollients, cosmetic bases and moisturizers for the face and body. It exhibits certain surface penetrating characteristics that can increase the penetration of compositions through human skin. It is therapeutically used in methods for lowering cholesterol, triglycerides and low density lipoproteins and increasing high density lipoproteins. It is believed by many to prevent and treat allergies, prevent scarring, treat headaches, prevent nosebleeds, treat cold and flu symptoms, and relieve discomfort associated with menstruation. It is known to be ingested by spoon, dropper, tablet, gelatin capsule, time release capsules, and as a food additive. It can be administered in the form of emulsions, suspensions, and powders. Topically, it can be administered in creams, lotions, oils, powders, and gels.
- Some fruits are known to be high in anti-oxidants and have proven effective in improving health. Blueberries, pomegranates, plums, cranberries, black chokeberries ( sanbucus nigra ), black elderberries, and cherries are all relatively high in anti-oxidants.
- cherries are known to provide a variety of additional health benefits.
- Tart cherries prunus cerasus
- Montmorency and Balaton varieties have been shown to be a particularly good source of bioflavonoids in addition to anti-oxidants.
- anthocyanins from cherries are known to be an effective anti-inflammatory agent.
- Melatonins from cherries are known to be an effective anti-oxidant. Both have been found to reduce cancers.
- Cherries are also believed to assist in the proper balancing of certain hormones. Indeed, cherries are commonly called “the healing fruit.”
- compositions comprising emu oil and processed whole fruit, preferably a fruit selected from the group including blueberries, pomegranates, plums, cranberries, black chokeberries, black elderberries, and cherries.
- the composition includes emu oil and whole cherries or at least one substance extracted from whole cherries.
- the substance is from the group consisting of anthocyanins, melatonins, phenolics, and flavonoids.
- the invention comprises a composition formed of emu oil and fruit.
- the emu oil is processed in that it is refined to remove impurities, discoloration, etc.
- a preferred process for refining emu oil is commonly termed “cold rendering” in which the temperature of the oil is not raised too high so as to make it unstable.
- a preferred emu oil for use in the present invention can be obtained from L. B. Processors LLC, 1846 Mosley Ferry Rd., Chapmansboro, Tenn. 37035. It is believed that any other emu oil having a similar composition is substantially equally effective for purposes of the invention.
- a preferred fruit includes cherries, and preferably tart cherries of the Montmorency or Balaton varieties. Sweet cherries can also provide similar benefits.
- the cherries are preferably provided in the form of a cherry concentrate.
- the cherry concentrate is made in a conventional manner by squeezing and cooking down whole cherries preferably to a concentration of 68 brix.
- the term “brix” is used in its conventional meaning of a unit of measure of sucrose (the percent of sugar in 100 g of cane sugar solution).
- a concentration greater or lesser than 68 brix is acceptable, preferably within a range of plus or minus seven brix.
- Montmorency cherries it takes about 88 lbs. of cherries to render 1 gallon of cherry concentrate.
- Cherry concentrates within the preferred range of concentration are commercially available.
- cherries is a freeze dried powder manufactured by a vacuum freeze drying process.
- a commercial source of freeze dried red tart cherry powder is Crystals International, Inc., 600 West Dr. M. L. King, Jr. Blvd., Plant City, Fla. This product contains 70% red Tart cherry juice concentrate.
- Cherry powder can also be made in spray dry, drum dry and pan dry processes.
- Other acceptable forms of cherries include cherry purees and Elliott cherries (similar to a puree, but with bigger pieces of whole cherries).
- the emu oil and cherries are combined to form a cream, oil, or lotion for topical use on human skin.
- a preferred composition will include a range of 1% to 20% emu oil, and 2% to 15% cherries, by weight. All of the natural health benefits of the cherries such as those found in specified compounds including anthocyanins and melatonins are transported subcutaneously by the emu oil's penetration of the skin. It may be advisable to provide other compounds in the composition to enhance solubility and viscosity characteristics. Such compounds might include water, glycerin, and well known emulsions that are common to cosmetics, creams and oils.
- emu oil and cherries are reduced to a form for internal administration.
- a form for internal administration is an oral administration comprising a gelatin capsule of the composition.
- Other examples include a powdered form of composition in a capsule, or a dried form of the composition pressed into a tablet.
- a preferred composition for oral administration will include a range of 1% to 35% emu oil, and 1% to 45% cherries, by weight.
- the composition can be administered systemically such as by subcutaneous or intramuscular injection. It can also be administered orally by solution, or emulsion with fewer side effects.
- compositions improves digestion, retards the aging process, reduces the inflammation of arthritis and gout, protects against certain types of cancer and heart disease, assists in stabilizing and balancing hormones, neutralizes free radicals, reduces short-term memory loss, aids in combating stress, reduces high strain and fatigue, reduces LDL cholesterol, improves the bodies of certainty in rhythms and natural sleep patterns, and maintains a long, stable shelf life, all without disruptive side effects.
- the invention also encompasses compositions comprising emu oil and active ingredients extracted from whole cherries, such as cherry-derived anthocyanins and melatonins.
- composition can take the form of creams, pills, gelatin capsules, massage oils, lotions, gels, shampoos, soaps, conditioners, sprays, solids, and powders. It is believed that with certain emulsions well known to those of ordinary skill in the art, such products as car cleaners and floor cleaners can benefit from the composition. As well, it is believed that pet food can be enhanced by incorporating a combination of emu oil and fruit.
- cherries can be used in combination with emu oil for the particular benefits afforded by those fruits.
- fruits known to be high in anti-oxidants have proven effective.
- Blueberries, pomegranates, plums, cranberries, black chokeberries ( sanbucus nigra ), and black elderberries in concentrate form, in extracts, or in powders can be used instead of cherries. But they can also be used in addition to cherries.
- a sample formula will contain one part cherry concentrate, one part emu oil, one part omega 3 fish oil (pharmaceutical grade/toxin free), one part certified organic top grade flaxseed oil, and one part CoQ10. If taste must be enhanced, more cherry concentrate can be added.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Birds (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
Abstract
A composition is provided comprising emu oil and processed whole fruit. The composition is in a form for either topical application to human skin or for internal ingestion.
Description
- 1. Field of the Invention
- The invention relates to compositions suitable for topical application to human skin and suitable for ingesting, and, more particularly, to natural compositions comprising emu oil and various fruits.
- 2. Description of the Related Art
- Emu oil (also known as kalaya oil) is rendered from the bird's fat. It is used in cosmetics and cosmetic related items, including wrinkle retarding emollients, cosmetic bases and moisturizers for the face and body. It exhibits certain surface penetrating characteristics that can increase the penetration of compositions through human skin. It is therapeutically used in methods for lowering cholesterol, triglycerides and low density lipoproteins and increasing high density lipoproteins. It is believed by many to prevent and treat allergies, prevent scarring, treat headaches, prevent nosebleeds, treat cold and flu symptoms, and relieve discomfort associated with menstruation. It is known to be ingested by spoon, dropper, tablet, gelatin capsule, time release capsules, and as a food additive. It can be administered in the form of emulsions, suspensions, and powders. Topically, it can be administered in creams, lotions, oils, powders, and gels.
- Some fruits are known to be high in anti-oxidants and have proven effective in improving health. Blueberries, pomegranates, plums, cranberries, black chokeberries (sanbucus nigra), black elderberries, and cherries are all relatively high in anti-oxidants.
- Consumption of cherries and its products are known to provide a variety of additional health benefits. Tart cherries (prunus cerasus), especially the Montmorency and Balaton varieties, have been shown to be a particularly good source of bioflavonoids in addition to anti-oxidants. For example, anthocyanins from cherries are known to be an effective anti-inflammatory agent. Melatonins from cherries are known to be an effective anti-oxidant. Both have been found to reduce cancers. Cherries are also believed to assist in the proper balancing of certain hormones. Indeed, cherries are commonly called “the healing fruit.”
- It is known to extract components from cherries and utilize them in other compositions such as food additives and supplements. For example, flavonoids have been extracted from tart cherries and incorporated into foods. It is also known to combine alpha-hydroxy acids with emu oil to provide moisturizing creams and lotions. Cherries are known to be a source of malic acid which is a type of alpha-hydroxy acid. Also, it is known to combine pitted tart cherries with comminuted meat to increase moisture, reduce fat content, and improve flavor. However, the full benefits of fruits and emu oil have yet to be realized.
- According to the invention, more of the benefits of emu oil and fruits can be realized by a composition comprising emu oil and processed whole fruit, preferably a fruit selected from the group including blueberries, pomegranates, plums, cranberries, black chokeberries, black elderberries, and cherries. In one aspect, the composition includes emu oil and whole cherries or at least one substance extracted from whole cherries. The substance is from the group consisting of anthocyanins, melatonins, phenolics, and flavonoids.
- The following description primarily addresses a preferred embodiment of the present invention. Those skilled in the article readily recognize, however, that the invention may be satisfactorily employed in other applications, and that alternative aspects and embodiments of the invention are possible. All those other applications, aspects and embodiments of the invention are hereby expressly included in, and form a part of, the invention.
- The invention comprises a composition formed of emu oil and fruit. Preferably, the emu oil is processed in that it is refined to remove impurities, discoloration, etc. A preferred process for refining emu oil is commonly termed “cold rendering” in which the temperature of the oil is not raised too high so as to make it unstable. A preferred emu oil for use in the present invention can be obtained from L. B. Processors LLC, 1846 Mosley Ferry Rd., Chapmansboro, Tenn. 37035. It is believed that any other emu oil having a similar composition is substantially equally effective for purposes of the invention.
- A preferred fruit includes cherries, and preferably tart cherries of the Montmorency or Balaton varieties. Sweet cherries can also provide similar benefits. The cherries are preferably provided in the form of a cherry concentrate. The cherry concentrate is made in a conventional manner by squeezing and cooking down whole cherries preferably to a concentration of 68 brix. The term “brix” is used in its conventional meaning of a unit of measure of sucrose (the percent of sugar in 100 g of cane sugar solution). A concentration greater or lesser than 68 brix is acceptable, preferably within a range of plus or minus seven brix. Using Montmorency cherries, it takes about 88 lbs. of cherries to render 1 gallon of cherry concentrate. Cherry concentrates within the preferred range of concentration are commercially available.
- Another preferred form of cherries is a freeze dried powder manufactured by a vacuum freeze drying process. A commercial source of freeze dried red tart cherry powder is Crystals International, Inc., 600 West Dr. M. L. King, Jr. Blvd., Plant City, Fla. This product contains 70% red Tart cherry juice concentrate. Cherry powder can also be made in spray dry, drum dry and pan dry processes. Other acceptable forms of cherries include cherry purees and Elliott cherries (similar to a puree, but with bigger pieces of whole cherries).
- In one form, the emu oil and cherries are combined to form a cream, oil, or lotion for topical use on human skin. A preferred composition will include a range of 1% to 20% emu oil, and 2% to 15% cherries, by weight. All of the natural health benefits of the cherries such as those found in specified compounds including anthocyanins and melatonins are transported subcutaneously by the emu oil's penetration of the skin. It may be advisable to provide other compounds in the composition to enhance solubility and viscosity characteristics. Such compounds might include water, glycerin, and well known emulsions that are common to cosmetics, creams and oils.
- In another form, emu oil and cherries are reduced to a form for internal administration. One example is an oral administration comprising a gelatin capsule of the composition. Other examples include a powdered form of composition in a capsule, or a dried form of the composition pressed into a tablet. A preferred composition for oral administration will include a range of 1% to 35% emu oil, and 1% to 45% cherries, by weight. In liquid form, the composition can be administered systemically such as by subcutaneous or intramuscular injection. It can also be administered orally by solution, or emulsion with fewer side effects.
- It is believed that the composition improves digestion, retards the aging process, reduces the inflammation of arthritis and gout, protects against certain types of cancer and heart disease, assists in stabilizing and balancing hormones, neutralizes free radicals, reduces short-term memory loss, aids in combating stress, reduces high strain and fatigue, reduces LDL cholesterol, improves the bodies of certainty in rhythms and natural sleep patterns, and maintains a long, stable shelf life, all without disruptive side effects. The invention also encompasses compositions comprising emu oil and active ingredients extracted from whole cherries, such as cherry-derived anthocyanins and melatonins.
- It will be apparent that the composition can take the form of creams, pills, gelatin capsules, massage oils, lotions, gels, shampoos, soaps, conditioners, sprays, solids, and powders. It is believed that with certain emulsions well known to those of ordinary skill in the art, such products as car cleaners and floor cleaners can benefit from the composition. As well, it is believed that pet food can be enhanced by incorporating a combination of emu oil and fruit.
- Of course other fruits can be used in combination with emu oil for the particular benefits afforded by those fruits. For example, fruits known to be high in anti-oxidants have proven effective. Blueberries, pomegranates, plums, cranberries, black chokeberries (sanbucus nigra), and black elderberries in concentrate form, in extracts, or in powders can be used instead of cherries. But they can also be used in addition to cherries.
- It is believed that the addition of other ingredients can enhance the benefits of the composition. The addition of coenzyme Q10 has also been shown to aid with heart disease, brain diseases and periodontal diseases. A sample formula will contain one part cherry concentrate, one part emu oil, one part omega 3 fish oil (pharmaceutical grade/toxin free), one part certified organic top grade flaxseed oil, and one part CoQ10. If taste must be enhanced, more cherry concentrate can be added.
- While the invention has been specifically described in connection with certain specific embodiments thereof, it is to be understood that this is by way of illustration and not of limitation, and the scope of the appended claims should be construed as broadly as the prior art will permit.
Claims (9)
1. A composition comprising emu oil and processed fruit.
2. The composition of claim 1 wherein the processed fruit is selected from a group consisting of blueberries, pomegranates, plums, cranberries, black chokeberries (sambucus nigra), cherries, and black elderberries.
3. The composition of claim 2 wherein the processed fruit is whole cherries.
4. The composition of claim 3 comprising a range of 1% to 20% emu oil, and 2% to 15% fruit, by weight.
5. The composition of claim 3 in any of the form of creams, pills, gelatin capsules, massage oils, lotions, gels, shampoos, soaps, conditioners, sprays, solids, and powders.
6. The composition of claim 3 comprising a range of 1% to 35% emu oil, and 1% to 45% cherries.
7. The composition of claim 2 comprising a range of 1% to 20% emu oil, and 2% to 15% fruit, by weight.
8. The composition of claim 1 comprising a range of 1% to 20% emu oil, and 2% to 15% fruit, by weight.
9. A composition comprising emu oil and at least one substance extracted from whole cherries wherein the substance is one of the group consisting of anthocyanins, melatonins, phenolics, and flavonoids.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/572,851 US20080057116A1 (en) | 2004-07-28 | 2005-07-28 | Emu Oil and Fruit Composition |
US12/486,327 US7939107B2 (en) | 2004-07-28 | 2009-06-17 | Emu oil and fruit composition |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52196504P | 2004-07-28 | 2004-07-28 | |
US59385205P | 2005-02-18 | 2005-02-18 | |
PCT/US2005/026782 WO2006015119A2 (en) | 2004-07-28 | 2005-07-28 | Emu oil and fruit composition |
US11/572,851 US20080057116A1 (en) | 2004-07-28 | 2005-07-28 | Emu Oil and Fruit Composition |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/026782 A-371-Of-International WO2006015119A2 (en) | 2004-07-28 | 2005-07-28 | Emu oil and fruit composition |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/486,327 Continuation US7939107B2 (en) | 2004-07-28 | 2009-06-17 | Emu oil and fruit composition |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080057116A1 true US20080057116A1 (en) | 2008-03-06 |
Family
ID=35787823
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/572,851 Abandoned US20080057116A1 (en) | 2004-07-28 | 2005-07-28 | Emu Oil and Fruit Composition |
US12/486,327 Active 2025-10-12 US7939107B2 (en) | 2004-07-28 | 2009-06-17 | Emu oil and fruit composition |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/486,327 Active 2025-10-12 US7939107B2 (en) | 2004-07-28 | 2009-06-17 | Emu oil and fruit composition |
Country Status (9)
Country | Link |
---|---|
US (2) | US20080057116A1 (en) |
EP (1) | EP1771185A4 (en) |
JP (1) | JP2008508301A (en) |
CN (1) | CN101065132A (en) |
AU (1) | AU2005269382A1 (en) |
CA (1) | CA2574968C (en) |
MX (1) | MX2007001098A (en) |
RU (1) | RU2007103125A (en) |
WO (1) | WO2006015119A2 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090192126A1 (en) * | 2006-04-12 | 2009-07-30 | John Casey | Oral Composition Comprising a Polyunsaturated Fatty Acid and Salicylic Acid for Obtaining an Antiinflammatory Effect in Skin |
US8562976B2 (en) | 2004-01-22 | 2013-10-22 | University Of Miami | Co-enzyme Q10 formulations and methods of use |
US20150231060A1 (en) * | 2013-03-14 | 2015-08-20 | 3 In 1 Dental Pllc | Compositions for treatment of xerostomia and for tooth treatment |
US20170304187A1 (en) * | 2011-06-08 | 2017-10-26 | Scott A. Weisenfluh | EMU Oil In Combination With Other Active Ingredients For Treating Skin Imperfections |
US9896731B2 (en) | 2009-05-11 | 2018-02-20 | Berg Llc | Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10) |
US9901542B2 (en) | 2013-09-04 | 2018-02-27 | Berg Llc | Methods of treatment of cancer by continuous infusion of coenzyme Q10 |
US10376477B2 (en) | 2011-04-04 | 2019-08-13 | Berg Llc | Method of treating or preventing tumors of the central nervous system |
US10668028B2 (en) | 2008-04-11 | 2020-06-02 | Berg Llc | Methods and use of inducing apoptosis in cancer cells |
US10933032B2 (en) | 2013-04-08 | 2021-03-02 | Berg Llc | Methods for the treatment of cancer using coenzyme Q10 combination therapies |
US12303471B2 (en) | 2015-11-16 | 2025-05-20 | Bpgbio, Inc. | Methods of treatment of temozolomide-resistant glioma using coenzyme Q10 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070196298A1 (en) * | 2005-05-31 | 2007-08-23 | Kostick Richard H | Cosmetic and dermatological formulations with natural pigments and methods of use |
CN101495124A (en) * | 2006-06-01 | 2009-07-29 | 樱花资产有限责任公司 | Fucoidan compositions and methods |
US7494674B2 (en) | 2006-09-22 | 2009-02-24 | Lapointe Andrew T | Nutraceutical with tart cherries and method of treatment therewith |
CN102389378B (en) * | 2011-11-23 | 2012-12-12 | 天津郁美净集团有限公司 | Compound grease microemulsion used in cosmetics and preparation method thereof |
CN106138717A (en) * | 2015-03-25 | 2016-11-23 | 张爱民 | A kind of ointment treated for ice and preparation using method thereof |
US10806769B2 (en) | 2016-03-31 | 2020-10-20 | Gojo Industries, Inc. | Antimicrobial peptide stimulating cleansing composition |
AU2017240069B2 (en) | 2016-03-31 | 2024-03-07 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
US20190175680A1 (en) * | 2016-09-07 | 2019-06-13 | Nanosmart Fruit, Llc | Compositions comprising nanoparticles derived from whole fruit |
JP2020500860A (en) | 2016-11-23 | 2020-01-16 | ゴジョ・インダストリーズ・インコーポレイテッド | Disinfectant compositions containing probiotic / prebiotic active ingredients |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5472713A (en) * | 1994-11-23 | 1995-12-05 | Elf Resources, Inc. | Therapeutic uses of emu oil |
US5670200A (en) * | 1992-12-01 | 1997-09-23 | Pleva; Raymond M. | Cherry-containing meat product and method of making the same |
US6103246A (en) * | 1993-06-03 | 2000-08-15 | Tisdale; Carrie J. | Creams and lotions containing emu oil |
US6342208B1 (en) * | 1996-08-02 | 2002-01-29 | Plum Kerni Produktion A/S | Oil-in-water emulsion containing C10-C24 fatty acid derivatives for treating skin of mammals |
US20020055562A1 (en) * | 1998-10-29 | 2002-05-09 | Butuc S. Gina | Gel compositions |
US6407141B1 (en) * | 1995-11-15 | 2002-06-18 | Francis J. Hart | Oxalic acid or oxalate compositions and methods for vascular disorders, diseases, and calcerous conditions |
US20030031724A1 (en) * | 2001-05-16 | 2003-02-13 | Frank Orthoefer | Anti-inflammatory composition and method of using same |
US6531126B2 (en) * | 1999-08-26 | 2003-03-11 | Ganeden Biotech, Inc. | Use of emu oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications and preparations |
US6534086B1 (en) * | 2000-03-06 | 2003-03-18 | Metagenics, Inc. | Composition and method for treatment of inflammation and pain in mammals |
US6579543B1 (en) * | 2002-02-22 | 2003-06-17 | Jackie H. McClung | Composition for topical application to skin |
US20030175332A1 (en) * | 2001-07-31 | 2003-09-18 | Brown Harold G | Methods of preventing or treating diseases and conditions using complex carbohydrates |
US20050123479A1 (en) * | 2002-03-01 | 2005-06-09 | Antonio Ferrante | Therapeutic properties of oils |
US20050266064A1 (en) * | 2004-05-29 | 2005-12-01 | Mccarthy Kathryn J | Cosmetic compositions and methods |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5652007A (en) * | 1992-12-01 | 1997-07-29 | Pleva; Raymond M. | Method of making a cured cherry-containing meat product |
AU7472398A (en) | 1997-05-09 | 1998-11-27 | Medlogic Global Corporation | Compositions for cosmetic applications |
WO2000026285A1 (en) | 1998-10-29 | 2000-05-11 | Penreco | Gel compositions |
US20060073211A1 (en) * | 2001-06-18 | 2006-04-06 | Michael Marenick | Cellulite formulation containing whole egg |
US6773718B2 (en) | 2001-11-15 | 2004-08-10 | 3M Innovative Properties Company | Oil absorbent wipe with rapid visual indication |
AU2002950308A0 (en) * | 2002-07-23 | 2002-09-12 | Phoenix Eagle Company Pty Ltd | Topically applied composition |
US20080032032A1 (en) * | 2006-08-01 | 2008-02-07 | Pleva Raymond M | Cherry-based additive |
US7666859B2 (en) * | 2006-09-08 | 2010-02-23 | Norman Turkowitz | Skin compositions containing hydrocortisone |
US8623191B2 (en) * | 2006-09-22 | 2014-01-07 | Honeywell International Inc. | Non-volatile addressable electronic paper with gray level capability |
-
2005
- 2005-07-28 RU RU2007103125/15A patent/RU2007103125A/en not_active Application Discontinuation
- 2005-07-28 WO PCT/US2005/026782 patent/WO2006015119A2/en active Application Filing
- 2005-07-28 CN CNA2005800251988A patent/CN101065132A/en active Pending
- 2005-07-28 EP EP05776624A patent/EP1771185A4/en not_active Withdrawn
- 2005-07-28 CA CA2574968A patent/CA2574968C/en active Active
- 2005-07-28 JP JP2007523806A patent/JP2008508301A/en active Pending
- 2005-07-28 US US11/572,851 patent/US20080057116A1/en not_active Abandoned
- 2005-07-28 AU AU2005269382A patent/AU2005269382A1/en not_active Abandoned
- 2005-07-28 MX MX2007001098A patent/MX2007001098A/en active IP Right Grant
-
2009
- 2009-06-17 US US12/486,327 patent/US7939107B2/en active Active
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5670200A (en) * | 1992-12-01 | 1997-09-23 | Pleva; Raymond M. | Cherry-containing meat product and method of making the same |
US6103246A (en) * | 1993-06-03 | 2000-08-15 | Tisdale; Carrie J. | Creams and lotions containing emu oil |
US5472713A (en) * | 1994-11-23 | 1995-12-05 | Elf Resources, Inc. | Therapeutic uses of emu oil |
US5662921A (en) * | 1994-11-23 | 1997-09-02 | Elf Resources, Inc. | Therapeutic uses of emu oil |
US6407141B1 (en) * | 1995-11-15 | 2002-06-18 | Francis J. Hart | Oxalic acid or oxalate compositions and methods for vascular disorders, diseases, and calcerous conditions |
US6342208B1 (en) * | 1996-08-02 | 2002-01-29 | Plum Kerni Produktion A/S | Oil-in-water emulsion containing C10-C24 fatty acid derivatives for treating skin of mammals |
US20020055562A1 (en) * | 1998-10-29 | 2002-05-09 | Butuc S. Gina | Gel compositions |
US6881776B2 (en) * | 1998-10-29 | 2005-04-19 | Penreco | Gel compositions |
US6531126B2 (en) * | 1999-08-26 | 2003-03-11 | Ganeden Biotech, Inc. | Use of emu oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications and preparations |
US6733751B2 (en) * | 1999-08-26 | 2004-05-11 | Ganeden Biotech, Inc. | Use of Emu Oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications & preparations |
US6534086B1 (en) * | 2000-03-06 | 2003-03-18 | Metagenics, Inc. | Composition and method for treatment of inflammation and pain in mammals |
US20030031724A1 (en) * | 2001-05-16 | 2003-02-13 | Frank Orthoefer | Anti-inflammatory composition and method of using same |
US20030175332A1 (en) * | 2001-07-31 | 2003-09-18 | Brown Harold G | Methods of preventing or treating diseases and conditions using complex carbohydrates |
US6579543B1 (en) * | 2002-02-22 | 2003-06-17 | Jackie H. McClung | Composition for topical application to skin |
US20050123479A1 (en) * | 2002-03-01 | 2005-06-09 | Antonio Ferrante | Therapeutic properties of oils |
US20050266064A1 (en) * | 2004-05-29 | 2005-12-01 | Mccarthy Kathryn J | Cosmetic compositions and methods |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8562976B2 (en) | 2004-01-22 | 2013-10-22 | University Of Miami | Co-enzyme Q10 formulations and methods of use |
US8586030B2 (en) | 2004-01-22 | 2013-11-19 | University Of Miami | Co-enzyme Q10 formulations and methods of use |
US8771680B2 (en) | 2004-01-22 | 2014-07-08 | University Of Miami | Topical co-enzyme Q10 formulations and methods of use |
US8987329B2 (en) * | 2006-04-12 | 2015-03-24 | Conopco, Inc. | Oral composition comprising a polyunsaturated fatty acid and salicylic acid for obtaining an antiinflammatory effect in skin |
US20090192126A1 (en) * | 2006-04-12 | 2009-07-30 | John Casey | Oral Composition Comprising a Polyunsaturated Fatty Acid and Salicylic Acid for Obtaining an Antiinflammatory Effect in Skin |
US10668028B2 (en) | 2008-04-11 | 2020-06-02 | Berg Llc | Methods and use of inducing apoptosis in cancer cells |
US11028446B2 (en) | 2009-05-11 | 2021-06-08 | Berg Llc | Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10) |
US9896731B2 (en) | 2009-05-11 | 2018-02-20 | Berg Llc | Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10) |
US12209285B2 (en) | 2009-05-11 | 2025-01-28 | Bpgbio, Inc. | Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10) |
US10351915B2 (en) | 2009-05-11 | 2019-07-16 | Berg Llc | Methods for treatment of oncological disorders using an epimetabolic shifter (Coenzyme Q10) |
US10519504B2 (en) | 2009-05-11 | 2019-12-31 | Berg Llc | Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
US11452699B2 (en) | 2011-04-04 | 2022-09-27 | Berg Llc | Method of treating or preventing tumors of the central nervous system |
US10376477B2 (en) | 2011-04-04 | 2019-08-13 | Berg Llc | Method of treating or preventing tumors of the central nervous system |
US20170304187A1 (en) * | 2011-06-08 | 2017-10-26 | Scott A. Weisenfluh | EMU Oil In Combination With Other Active Ingredients For Treating Skin Imperfections |
US20150231060A1 (en) * | 2013-03-14 | 2015-08-20 | 3 In 1 Dental Pllc | Compositions for treatment of xerostomia and for tooth treatment |
US9968547B2 (en) * | 2013-03-14 | 2018-05-15 | 3 In 1 Dental Pllc | Compositions for treatment of xerostomia and for tooth treatment |
US10933032B2 (en) | 2013-04-08 | 2021-03-02 | Berg Llc | Methods for the treatment of cancer using coenzyme Q10 combination therapies |
US11298313B2 (en) | 2013-09-04 | 2022-04-12 | Berg Llc | Methods of treatment of cancer by continuous infusion of coenzyme Q10 |
US9901542B2 (en) | 2013-09-04 | 2018-02-27 | Berg Llc | Methods of treatment of cancer by continuous infusion of coenzyme Q10 |
US12303471B2 (en) | 2015-11-16 | 2025-05-20 | Bpgbio, Inc. | Methods of treatment of temozolomide-resistant glioma using coenzyme Q10 |
Also Published As
Publication number | Publication date |
---|---|
EP1771185A4 (en) | 2009-09-23 |
US20090258080A1 (en) | 2009-10-15 |
AU2005269382A1 (en) | 2006-02-09 |
MX2007001098A (en) | 2009-02-11 |
RU2007103125A (en) | 2008-09-10 |
JP2008508301A (en) | 2008-03-21 |
WO2006015119A2 (en) | 2006-02-09 |
EP1771185A2 (en) | 2007-04-11 |
CN101065132A (en) | 2007-10-31 |
US7939107B2 (en) | 2011-05-10 |
CA2574968A1 (en) | 2006-02-09 |
CA2574968C (en) | 2014-05-20 |
WO2006015119A3 (en) | 2006-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7939107B2 (en) | Emu oil and fruit composition | |
US20220296552A1 (en) | Compositions and methods for acutely raising nitic oxide levels | |
Javed | Aloe vera gel in food, health products, and cosmetics industry | |
US20070085058A1 (en) | Nanoemulsion compositions and methods of use thereof | |
US20110060039A1 (en) | Composition | |
US20140378543A1 (en) | Methods of producing and using nutritional and pharmaceutical compositions that include one or more active substances | |
WO2002070012A1 (en) | Dietary supplement compositions | |
KR102178926B1 (en) | A composition for reinforcing immune function and anti-fatigue comprising fermented placenta and its use | |
US9125430B2 (en) | Stable and bioavailable compositions of isomers of carotenoids for skin and hair | |
JP4603269B2 (en) | Use of horse milk concentrate dried on highly dispersible substrates without bioactivity | |
KR102154092B1 (en) | A compostion comprising Torreya nucifera seed extract or its fraction having anti-oxidation or anti-inflammation activity | |
KR102119307B1 (en) | Composition for Anti-inflammation Using Extract of Salix sp. Plant | |
JP2023509324A (en) | Composition for prevention, improvement or treatment of atopic dermatitis disease | |
KR20170045085A (en) | Composition for improving skin and its use | |
KR20150120741A (en) | Composition for preventing or improving atopic dermatitis comprising mixture of persimmon peel, persimmon flesh, persimmon leaf and Diospyros lotus leaf as effective component | |
KR20200084215A (en) | Anti-inflammatory composition comprising extract of Polyopes affinis | |
KR102369909B1 (en) | Composition for Anti-allergy Using an Extract of Bistorta manshuriensis | |
JP4809611B2 (en) | Fat cell fat accumulation inhibitor | |
Chabib et al. | Therapeutic potential of cinnamon oil from Indonesia: Nanotechnology-essential oil | |
US20040131636A1 (en) | Blood fluidity-improving health foods | |
KR20220105462A (en) | Pharmaceutical composition for preventing or treating inflammatory disease comprising extracts of Chaenomeles japonica (Thunb.) Lindl. and Safflower seed | |
JP2021120358A (en) | Oral skin barrier function improver | |
JP2023033042A (en) | Qol-improving composition | |
Sachdev et al. | Health Benefit, Traditional, and Modern T Uses of Natural Honey SmSS | |
KR20170133821A (en) | Composition for relieving hot flush or osteoporosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |